Anticancer Drugs Course
This course equips oncology professionals with practical skills to manage first-line EGFR TKI therapies for EGFR-mutant NSCLC. Learners will master treatment selection based on evidence, toxicity prevention and control, resistance assessment and second-line planning, and effective patient communication to improve outcomes and confidence in care decisions.

from 4 to 360h flexible workload
valid certificate in your country
What will I learn?
Gain a practical overview of first-line systemic treatments for EGFR-mutated NSCLC, covering targeted therapies, chemo-immunotherapy, and chemotherapy. Explore drug mechanisms, dosing schedules, toxicity management, resistance mechanisms, follow-up options, monitoring protocols, and communication skills for evidence-based patient care.
Elevify advantages
Develop skills
- Select EGFR TKI treatments using latest trial data.
- Plan resistance tests like scans, biopsies, and liquid biopsies.
- Match resistance to next-line targeted, chemo, or trial therapies.
- Prevent and handle EGFR TKI side effects like rash, diarrhoea, lung issues, and low blood counts.
- Counsel patients clearly on treatment aims, effects, and next steps.
Suggested summary
Before starting, you can change the chapters and the workload. Choose which chapter to start with. Add or remove chapters. Increase or decrease the course workload.What our students say
FAQs
Who is Elevify? How does it work?
Do the courses have certificates?
Are the courses free?
What is the course workload?
What are the courses like?
How do the courses work?
What is the duration of the courses?
What is the cost or price of the courses?
What is an EAD or online course and how does it work?
PDF Course